Retrospective analysis of prognostic factors of the skin melanoma patients with local tumor excision and the patients with regional lymphadenectomy;Retrospektywna ocena czynników ryzyka u pacjentów z czerniakiem skóry po regionalnej limfadenektomii oraz pacjentów jedynie po miejscowym wycieciu guza

Postepy Dermatologii i Alergologii

Volumn 24, Issue 1, 2007, Pages 26-34

  Kycler, Witold ^a   Teresiak, Marek ^a  

^a GREATER POLAND CANCER CENTRE   (Poland)

Author keywords

Lymph nodes; Melanoma; Prognostic factors

Indexed keywords

ARTICLE; CANCER GRADING; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; LYMPHADENECTOMY; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MELANOMA; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SKIN ULCER; STATISTICAL SIGNIFICANCE; SUPERFICIAL CANCER; SURVIVAL TIME; UNIVARIATE ANALYSIS; VISCERAL METASTASIS;

EID: 34247255557     PISSN: 1642395X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Ruka W. Algorytm postȩpowania. W: Czerniaki skóry u dorosłych. Ruka W, Nowecki ZI, Rutkowski P (red.). Medipage, Warszawa 2005; 136-9.
2. Balch CM, Soong SJ, Atkins MB, et al. An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin 2004; 54: 131-49.
3. Balch CM, Soong SJ, Gershenwald J, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the AJCC melanoma Stasing system. J Clin Oncol 2001; 19: 3622-34.
4. Essner R, Chung MH, Bleicher R, et al. Prognostic implication of trick (≥4 mm) melanoma in the area of ntraoperative lymphatic mapping and sentinel lymphadenectomy. Ann Surg Oncol 2002; 9: 754-61.
5. Liszkay G, Orsz Z, Peley G, et al. Relationship between sentinel lymph node status and regression of primary malignant melanoma. Mel Res 2005; 15: 509-13.
6. Cohran AJ, Pihl E, Wen DR, et al. Zoned immune suppressiono of lymph nodes draining malignant melanoma. Histologic and immunohistologic studies. J Natl Cancer Inst 1997; 78: 399-405.
7. Farzad Z, Mi Bride WH, Ogbechi H, et al. Lymphocytes from lymph nodes different distances from human melanoma vary in their capacity inhibit/ enhance tumor cell growth in vitro. Melanoma Res 1997; 7: 59-65.
8. Slingluff CL Jr., Engelhard VH, Ferrone S. Peptide and dendritic cell vaccines. Clin Cancer Res 2006; 12: 2342-45.
9. Cascinelli N, Belli F, Santinami M, et al. Sentinel lymph node biopsy in cutaneous melanoma: the WHO Melanoma Program experience. Ann Surg Oncol 2000; 7: 469-74.
10. Stokkel A, Bergman W, Pauwels EI
11. Wagner JD, Gordon MS, Chuang TY, et al. Predicting sentinel and residual lymph node basin disease after sentinel lymph node biopsy for melanoma. Cancer 2000; 89: 453-62.
12. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19: 3635-48.
13. Essner R, Morton DL. Does the tumor status of the regional lymph nodes really matter in melanoma? Ann Surg Oncel 2001; 8: 749-51.
14. Starz H, Balda BR, Kramer KU, et al. A micromorphometry based concept for routine staging classification of sentinel lymph node metastases and its clinical relevance in melanoma patients. Cancer 2001; 91: 2110-21.
15. Scott RN, McK
16. Shen P, Guenter IM, Wanek LA, et al. Can elective lymph node dissection decrease the frequency and mortality rate of late melanoma reccurences? Ann Surg Oncol 2000; 7: 114-9.
17. White RR, Stanley WE, Johnson JL, et al. Long-term survival in 2,505 patients with melanoma with regional lymph node metastasis. Ann Surg 2002; 235: 879-87.
18. Marghoob AA, Kroenig K, Bittencourt FV, et al. Breslow thickness and Clark level in melanoma: support for including level in pathology reports and in American Joint Committee on Cancer Staging. Cancer 2000; 1: 589-95.
19. Ahmed J. Malignant melanoma: prognostic indicators. Mayo Clin Proc 1997; 72: 356-61.
20. Kycler W, Grodecka S, Teresiak M i wsp. Wpływ wybranych cech klinicznych i morfologicznych na czas przeżycia chorych na czerniaka skóry. Współczesna Onkologia 2001; 5: 52-7.
21. Levi F, Randim bison L, La Vecchia C, et al. Prognostic factors for cutaneous malignant melanoma in Vaud, Switzerland. Int J Cancer 1998; 29: 315-9.
22. Stokkel A, Bergman W, Pauwels EKJ. Cutaneus malignant melanoma: clinical aspects, imaging modalities and treatment. Eur J Nuclear Med 2000; 27: 447-58.
23. Balzi D, Carli P, Giannotti B, et al. Skin melanoma in Italy: a population-based study on survival and prognostic factors. Eur J Cancer 1998; 34: 699-704.
24. Massi D, Franchi A, Borgognoni L, et al. Thin cutaneous malignant melanomas (